2 assets in Atypical Lobular Breast Hyperplasia

Therapeutic assets addressing Atypical Lobular Breast Hyperplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Exemestane Atypical Lobular Breast Hyperplasia	Dana-Farber Cancer Institute	P2	CCC (53)
Tamoxifen Atypical Lobular Breast Hyperplasia	Dana-Farber Cancer Institute	P2	CCC (53)